SUANFARMA is joining forces with Reyoung Pharmaceutical, for anti-infective and antibacterial API production. The technology developed by SUANFARMA involves flow chemistry, improving yields, selectivity, and reproducibility of the processes. It minimizes reaction times and requires smaller quantities of reagents and solvents, reducing raw material use and environmental impact. In addition, this technique is generally safer than traditional synthesis, reducing the risk of explosions and leaks of hazardous reagents.

“We are thrilled to join forces with SUANFARMA as we embark on this transformative collaboration, which marries innovation with exceptional product delivery,” said Manyi Xie Reyoung pharmaceutical vice-president. This alliance marks the beginning of an exciting journey, and we are confident that our collaboration will deliver immense value to our customers and partners by harnessing the unique strengths and capabilities of each organization.”

“This important strategic agreement between Reyoung and SUANFARMA highlights our shared commitment to technology-driven innovation and maximizing efficiency in order to provide superior products to the patients,” said Javier Calvo, R&D Director. “Reyoung’s exceptional partnership as our ally strengthens our global position, marking the first milestone in what we anticipate will be an immensely promising collaboration between our organizations.”